Physician profile
Ashley E Johnson
NPI 1881956027
$5,304.69
in general payments reported to CMS, 2019-2025
41 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $787 · 2022: $565 · 2023: $824 · 2024: $1,275 · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,952.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $981.28 | 2021-2025 | |
| Lilly USA, LLC | $544.72 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $478.00 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $469.55 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $438.87 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $273.60 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.87 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.12 | 2022-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $175.30 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $115.39 | 2021-2024 | |
| Amgen INC. | $113.89 | 2021-2025 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.46 | 2021 | |
| Abbott Laboratories | $90.55 | 2024-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $83.67 | 2024-2025 | Auvelity, Symbravo |
| Merck Sharp & Dohme LLC | $80.92 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.